|
|
||||||||
Clinical Investigations |
1 Department of Nuclear Medicine, University of Mainz, Mainz, Germany
2 Division of Nuclear Medicine, Department of Radiology, Johns Hopkins Medical Institutions, Baltimore, Maryland
3 Department of Psychiatry, University of Mainz, Mainz, Germany
4 Institute for Nuclear Chemistry, University of Mainz, Mainz, Germany
5 PET Center and Center for Functionally Integrative Neuroscience, Aarhus, Denmark
6 Department of Psychiatry and Psychotherapy, RWTH Aachen University, Aachen, Germany
11C-Raclopride has been widely used for PET studies of dopamine D2/3 receptors in human brain. The long half-life of 18F may impart advantages to the novel moderate-affinity benzamide 18F-desmethoxyfallypride and its high-affinity congener 18F-fallypride for competition studies and for detection of extrastriatal binding. However, the in vivo kinetics of these compounds and the quantification approaches for parametric mapping of their specific bindings have not been systematically compared. Methods: Dynamic emission recordings of the 3 tracers were obtained in groups of healthy subjects. A conventional model, graphical analysis using metabolite-corrected arterial inputs, and models with reference tissue inputs were used to calculate voxelwise parametric maps of the equilibrium distribution volume (Vd) and the binding potential (BP) of the 3 radioligands in brain. To test for bias, voxelwise kinetic results were compared with those obtained by volume-of-interest (VOI) analysis. Results: The Vd and BP estimates obtained by VOI analysis did not differ from the mean of voxelwise estimates in the same striatal volumes. In striatum, the mean 18F-desmethoxyfallypride BP ranged from 1.9 to 2.5, whereas the mean 11C-raclopride BP ranged from 3 to 4, depending on the method used for calculation. In contrast, the mean BP of 18F-fallypride ranged from 16 to 27 in striatum and could also be readily quantified in the thalamus. Conclusion: Reference tissue methods for the voxelwise calculation of binding parameters are suitable for parametric mapping of the 3 dopamine D2/3 receptor ligands.
Key Words: fallypride raclopride desmethoxyfallypride quantification binding potential parametric
This article has been cited by other articles:
![]() |
G. Grunder, C. Fellows, H. Janouschek, T. Veselinovic, C. Boy, A. Brocheler, K. M. Kirschbaum, S. Hellmann, K. M. Spreckelmeyer, C. Hiemke, et al. Brain and Plasma Pharmacokinetics of Aripiprazole in Patients With Schizophrenia: An [18F]Fallypride PET Study Am J Psychiatry, August 1, 2008; 165(8): 988 - 995. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Fehr, I. Yakushev, N. Hohmann, H.-G. Buchholz, C. Landvogt, H. Deckers, A. Eberhardt, M. Klager, M. N. Smolka, A. Scheurich, et al. Association of Low Striatal Dopamine D2 Receptor Availability With Nicotine Dependence Similar to That Seen With Other Drugs of Abuse Am J Psychiatry, April 1, 2008; 165(4): 507 - 514. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |